Why GLP-1 weight loss platforms struggle to scale without behavioural support
Lessons from real world digital health platforms on why behaviour change support becomes critical as GLP-1 services scale.

Most people building GLP-1 services pour their energy into the clinical and operational infrastructure. The prescribing, the compliance, the customer support, getting the medical side to scale. That is genuinely hard work, and it is where most of the pressure concentrates.
Which means the lifestyle and behaviour change layer often gets less focus than it deserves. Not because people think it does not matter, but because there is always something more urgent competing for attention.
Last year my team and I were working with the senior leadership of a very large weight management company. The business was growing fast, with demand accelerating month after month. The operational load had spread across the whole system at once: prescribers reviewing eligibility, patients asked for additional medical information, questions about side effects, dose increases, delivery issues, lifestyle support, and people wanting reassurance that what they were experiencing was normal.
In some of the weight management providers we have worked with across the UK and USA, inbound support volumes have run into the hundreds of thousands of contacts per month. At that scale, pressure stops being an inconvenience and starts becoming a clinical risk.
A question came up in those leadership discussions that I have now heard in several companies.
How much does the surrounding support actually matter?
The medication clearly works. That is why demand exists. But everything around it adds complexity, more teams, more systems, more cost. The argument goes: patients are losing weight, so why invest heavily in lifestyle support now? Focus on medication adherence and side effect management first. Deal with the lifestyle piece later, perhaps when patients start tapering or coming off the drug.
It is a reasonable question, and in the short term the numbers can seem to support it.
The evidence tells a different story. Lifestyle support is not just about behaviour change. It is about preventing muscle and bone loss, avoiding nutritional deficiencies, supporting mental health, and building the habits that sustain weight loss when patients eventually reduce or stop the medication. Without it, much of what the drug achieves can unwind quickly.
The question is not whether to offer lifestyle support. It is when and how to deliver it without overwhelming patients or services.
The real issue is rarely information. It is uncertainty.
People disengage from treatment for many reasons: cost, life circumstances, plateaus, or simply reaching their goal weight. Some take temporary breaks from treatment entirely, sometimes called drug holidays, a period where patients step back from medication, often losing contact with the service at exactly the moment they most need support.
But there is a particular pattern that comes up again and again. Uncertainty builds, patients feel unsupported, and there is no way to resolve that quickly at scale.
In GLP-1 services, that matters more than most platforms realise. Leaders we have worked with have told us that even a one or two percentage point improvement in retention can be worth more than almost any other intervention. The economics compound quickly. When uncertainty goes unaddressed, patient engagement drops and operational pressure rises together.
What we found, working across several of these services, is that many of those moments are predictable. They sit at specific points in the treatment journey: anxiety around the first medication dose, plateau periods, side effect spikes. They are not random. Across the services we have analysed, a significant proportion of inbound support contacts, in some cases over a third, relate to situations that proactive, well timed communication could have addressed before the patient ever needed to reach out.
When the system responds at those moments, sometimes with human support, sometimes automated, patients stay engaged longer and the support burden falls.
The companies getting this right are asking different questions. Not just what support to offer, but when it needs to reach patients, and what it needs to do at that specific point in the treatment journey.
This is the work we do at Sacher AI. We sit at the intersection of behavioural science, applied research, and clinical AI safety, helping health and weight management platforms build AI that is not just technically sound, but behaviourally safe and clinically trustworthy. Designing systems that adapt and respond in the right way at the right moment, from starting treatment through to long term maintenance, is where most of the real work sits.
If any of this reflects what your team is working through, I am happy to have a conversation.
Related blog updates




